Eli Lilly’s stock trades at a high forward earnings multiple, making Amgen a more affordable alternative. Amgen is developing a promising GLP-1 drug, MariTide, which may only need to be taken quarterly. With potential approval, MariTide could offer a more convenient option for consumers. Amgen’s stock is fairly valued and has room for growth, trading at a lower forward P/E ratio than Eli Lilly. The GLP-1 drug market shows significant growth potential, making Amgen a compelling healthcare stock to consider buying. The Motley Fool Stock Advisor team has identified 10 top stocks, with Amgen not included on the list.

Read more at Nasdaq MarketSite: Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.